nyuuzyou/wikis huggingface dataset:
Masitinib (AB-1010)

==General information==
Class/mechanism (from NCI Drug Dictionary): The orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK).
Route: PO
Extravasation: n/a
==Preliminary data==
===Gastrointestinal stromal tumor (GIST)===
# Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010 May;46(8):1344-51. Epub 2010 Mar 6. EuroPMC
# Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. Ann Oncol. 2014 Sep;25(9):1762-9. Epub 2014 Jul 25. link to original article link to PMC article EuroPMC
===Pancreatic cancer===
# AB07012: Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015 Jun;26(6):1194-200. Epub 2015 Apr 9. link to original article link to PMC article EuroPMC
===Systemic mastocytosis===
# AB06006: Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, Niedoszytko M, Barete S, Verstovsek S, Grattan C, Damaj G, Canioni D, Fraitag S, Lhermitte L, Georgin Lavialle S, Frenzel L, Afrin LB, Hanssens K, Agopian J, Gaillard R, Kinet JP, Auclair C, Mansfield C, Moussy A, Dubreuil P, Hermine O. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017 Feb 11;389(10069):612-620. Epub 2017 Jan 6. link to original article link to PMC article EuroPMC
==Also known as==
*Code name: AB-1010
Category:Drugs
Category:Oral medications
Category:FGFR inhibitors
Category:KIT inhibitors
Category:PDGFR inhibitors
Category:PTK2 inhibitors
Category:Gastrointestinal stromal tumor medications (investigational) 
Category:Pancreatic cancer medications (investigational) 
Category:Systemic mastocytosis medications (investigational)
Category:Investigational drugs
Mavorixafor (Xolremdi)

==Mechanism of action==
CXCR4 inhibitor
==Diseases for which it is established==
*WHIM syndrome
==History of changes in FDA indication==
*2024-04-30: Initial approval in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes. (Based on 4WHIM)
==Also known as==
*Brand name: Xolremdi
Category:Drugs
Category:Oral medications
Category:CXCR4 inhibitors
Category:WHIM syndrome medications
Category:FDA approved in 2024
Mayo Clinic College of Medicine and Science (Arizona) Hematology Oncology Fellowship

For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.
People affiliated with this program are cordially invited to add additional information.
"The Hematology/Oncology Fellowship at Mayo Clinic Arizona trains outstanding specialists in the fields of hematology and oncology who, at the end of three years, will demonstrate clinical expertise in the evaluation and treatment of hematologic and oncologic diseases through supervised intensive care of inpatients and longitudinal care of outpatients.
Our program combines well-rounded clinical training with opportunities to work with world-class investigators in a collegial environment."
==Basic information==
Name: Mayo Clinic College of Medicine and Science (Arizona) Hematology Oncology Fellowship
Fellowship program website: https://www.mayo.edu/mayo-clinic-school-of-graduate-medical-education/residencies-fellowships/internal-medicine-and-subspecialties/hematology-oncology-fellowship-arizona
ACGME ID: 1550313149
===Leadership===
*Program Director: Harshita R. Paripati, M.D.
===Fellowship Coordinator===
Jean R. Heiman
Phone: 480-342-6109
Email: heiman.jean@mayo.edu
==Application process and requirements==
https://www.mayo.edu/mayo-clinic-school-of-graduate-medical-education/residencies-fellowships/internal-medicine-and-subspecialties/hematology-oncology-fellowship-arizona/application-process
===Process===
*Applications accepted starting on:
*Application deadline: December 31
*Applications submitted through ERAS
===Requirements===
*Official medical school transcripts.
*Official test transcripts for candidates' examinations, such as USMLE, LMCC, COMLEX, NBOME, FMGEMS, FLEX or NBME
*Curriculum vitae (CV)
*Personal statement.
*Foreign medical school graduates only: ECFMG certificate
*Copy of your medical school diploma
*Accept J1 Visa
==Statistics==
*Number of fellowship positions available per year: 1
*Board certification eligibility upon fellowship completion: Hematology and Oncology
*Length of fellowship: 3 years
==Schedule==
https://www.mayo.edu/mayo-clinic-school-of-graduate-medical-education/residencies-fellowships/internal-medicine-and-subspecialties/hematology-oncology-fellowship-arizona/curriculum
===Year 1===
===Year 2===
===Year 3===
==Affiliated medical facilities==
*Mayo Clinic Hospital, Phoenix, Arizona
*Mayo Clinic Building — Phoenix (Mayo Clinic Cancer Center)
==Testimonials==
Testimonials from fellows are welcome. If you are a current or former fellow and would be willing to answer questions from applicants, please tell us and sign up for a free account so you can be listed here. Your email address will not be shared--messages will be sent through the site directly to the email address you provide us.
==Notable faculty==
To be listed by fellowship program.
Category:Hematology & Oncology fellowship programs
Mechlorethamine (Mustargen)

==General information==
Class/mechanism: Nitrogen mustard, alkylator. Crosslinks DNA, interfering with cell replication.Mechlorethamine (Mustargen) package insertMechlorethamine (Mustargen) package insert (locally hosted backup)
Route: IV, intracavitary, topical
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*HIV-associated lymphoma
*Classical Hodgkin lymphoma
==Diseases for which it was used==
*Diffuse large B-cell lymphoma
*Indolent lymphoma
==Patient drug information==
*Mechlorethamine (Mustargen) patient drug information (Chemocare)Mechlorethamine (Mustargen) patient drug information (Chemocare)
*Mechlorethamine (Mustargen) patient drug information (UpToDate)Mechlorethamine (Mustargen) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1949-03-15: Initial FDA approval (This is the first chemotherapy agent ever approved)
* 2004-02-09 (only label available at Drugs @ FDA):
# "Administered intravenously, is indicated for the palliative treatment of Hodgkin's disease (Stages III and IV), lymphosarcoma, chronic myelocytic or chronic lymphocytic leukemia, polycythemia vera, mycosis fungoides, and bronchogenic carcinoma."
# "Administered intrapleurally, intraperitoneally, or intrapericardially, is indicated for the palliative treatment of metastatic carcinoma resulting in effusion."
==Also known as==
*Generic name: chlormethine, nitrogen mustard
*Brand names: Ledaga, Mustargen, Mustine
==References==
Category:Drugs
Category:Intravenous medications
Category:Intracavitary medications
Category:Topical medications
Category:Vesicant
Category:Alkylating agents
Category:Nitrogen mustards
Category:HIV-associated lymphoma medications
Category:Classical Hodgkin lymphoma medications
Category:Diffuse large B-cell lymphoma medications (historic)
Category:Indolent lymphoma medications (historic)
Category:FDA approved in 1949
Medroxyprogesterone acetate (MPA)

==Diseases for which it is used==
*Endometrial cancer
==Diseases for which it was used==
*Breast cancer
*Renal cell carcinoma
==History of changes in FDA indication==
*1959-06-18: Initial approval
==History of changes in EMA indication==
*1959-08-20: EURD
==Also known as==
*Generic names: medroxyprogesterone acetate, MPA
*Brand names: Depo-Provera, Provera
Category:Drugs
Category:Oral medications
Category:Intramuscular medications
Category:Subcutaneous medications
Category:Progestins
Category:Endometrial cancer medications
Category:Breast cancer medications (historic)
Category:Renal cell carcinoma medications (historic)
Category:FDA approved in 1959
Category:EMA approved in 1959
Category:Stub
Megestrol (Megace)

==Diseases for which it is used==
*Endometrial cancer
==Diseases for which it was used==
*Breast cancer
*Renal cell carcinoma
==History of changes in EMA indication==
*1971-08-18: EURD
==Also known as==
*Code name: SC-10363
*Generic name: megestrol acetate
*Brand name: Maygace, Megace, Megestat, Megestil, Niagestin, Ovaban, Pallace
Category:Drugs
Category:Oral medications
Category:Progestins
Category:Appetite stimulants
Category:Endometrial cancer medications
Category:Breast cancer medications (historic)
Category:Renal cell carcinoma medications (historic)
Category:FDA approved in 1971
Category:EMA approved in 1971
Category:Stub
Melphalan flufenamide (Pepaxto)

Note: this drug has been withdrawn from the US market.
==Mechanism of action==
From the NCI Drug Dictionary: A peptide-drug conjugate composed of a peptide conjugated, via an aminopeptidase-targeting linkage, to the alkylating agent melphalan, with potential antineoplastic and anti-angiogenic activities. Upon administration, the highly lipophilic melphalan flufenamide penetrates cell membranes and enters cells. In aminopeptidase-positive tumor cells, melphalan flufenamide is hydrolyzed by peptidases to release the hydrophilic alkylating agent melphalan. This results in the specific release and accumulation of melphalan in aminopeptidase-positive tumor cells. Melphalan alkylates DNA at the N7 position of guanine residues and induces DNA intra- and inter-strand cross-linkages. This results in the inhibition of DNA and RNA synthesis and the induction of apoptosis, thereby inhibiting tumor cell proliferation. Peptidases are overexpressed by certain cancer cells. The administration of melphalan flufenamide allows for enhanced efficacy and reduced toxicity compared to melphalan.
==Additional information==
*Perspective on FDA withdrawal: Kanapuru et al. 2024 EuroPMC
==Diseases for which it is used==
Multiple myeloma
==History of changes in FDA indication==
===Multiple myeloma - WITHDRAWN===
*2021-02-26: Granted accelerated approval to in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody. (Based on HORIZONRRMM)
**2024-02-23: Accelerated approval withdrawn. (Based on OCEAN)
==History of changes in EMA indication==
*2022-08-17: Initial authorization as Pepaxti. Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one antiCD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
*Future date (positive CHMP summary of opinion): Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior lines of therapies, whose disease is refractory to lenalidomide and the last line of therapy.
==Also known as==
*Code name: J1
*Generic name: melflufen
*Brand named: Pepaxti, Pepaxto, Ygalo
Category:Drugs
Category:Intravenous medications
Category:Peptide-drug conjugates
Category:Alkylating agents
Category:Multiple myeloma medications
Category:FDA approved in 2021
Category:FDA withdrawn in 2024
Category:EMA approved in 2022
Melphalan for Injection-Hepatic Delivery System (Hepzato Kit)

==General information==
Class/mechanism: Nitrogen mustard, alkylator
==Toxicity management==
*REMS program information (FDA hosted)
==Diseases for which it is established==
*Uveal melanoma
==History of changes in FDA indication==
*2023-08-14: Initial approval as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. (Based on FOCUSHCC)
==Also known as==
*Brand name: Hepzato
==References==
#FOCUSHCC: NCT02678572
Category:Drugs
Category:Intra-arterial medications
Category:Alkylating agents
Category:Nitrogen mustards
Category:REMS program
Category:Uveal melanoma medications
Category:FDA approved in 2023
Category:Stub
Meningioma

Back to Top
Are you looking for a regimen but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
Last updated on 2024-07-23:0 regimens on this page
0 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==EANO==
*2016: Goldbrunner et al. EANO guidelines for the diagnosis and treatment of meningiomas EuroPMC 
==ISRS==
*2020: Marchetti et al. Stereotactic Radiosurgery for Intracranial Noncavernous Sinus Benign Meningioma: International Stereotactic Radiosurgery Society Systematic Review, Meta-Analysis and Practice Guideline EuroPMC
*2018: Lee et al. Stereotactic Radiosurgery for Benign (World Health Organization Grade I) Cavernous Sinus Meningiomas-International Stereotactic Radiosurgery Society (ISRS) Practice Guideline: A Systematic Review EuroPMC
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.
Category:Meningioma regimens
Category:Disease-specific pages
Category:CNS cancers
Meningioma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main meningioma page for regimens that include active anticancer treatment.
=Unresectable, all lines of therapy=
==Placebo==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator 	Comparative Efficacy
Ji et al. 2015 (SWOG S9005)	1992-1998 	Phase 3 (C)	Mifepristone	Did not meet primary endpoint of FFS
No active antineoplastic treatment.
===References===
# SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article EuroPMC NCT03015701
Category:Meningioma regimens
Category:Disease-specific pages
Category:CNS cancers
Category:Null regimens
Mepolizumab (Nucala)

==General information==
Class/mechanism: A humanized monoclonal antibody targeting interleukin-5 (IL-5). 
==Diseases for which it is used==
*Hypereosinophilic syndrome (HES)
==History of changes in FDA indication==
No approval for hematology/oncology conditions, at this time.
==Also known as==
*Brand names: Bosatria, Nucala
Category:Drugs
Category:Intravenous medications
Category:Anti-IL-5 antibodies
Category:Hypereosinophilic syndrome medications
Category:FDA approved in 2015
Merkel cell carcinoma - null regimens

Back to Top
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main MCC page for regimens that include active anticancer treatment.
=Adjuvant therapy=
==Observation==
===Regimen===
Study 	Dates of enrollment 	Evidence 	Comparator	Comparative Efficacy
Becker et al. 2023 (ADMEC-O)	2014-10-01 to 2020-08-31	Randomized Phase 2 (C)	Nivolumab 	Might have lower DFS12 (co-primary endpoint)
No systemic treatment after surgery.
====Preceding treatment====
*Surgery
===References===
#ADMEC-O: Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial. Lancet. 2023 Sep 2;402(10404):798-808. Epub 2023 Jul 11. Erratum in: Lancet. 2023 Oct 21;402(10411):1422. link to original article EuroPMC NCT02196961
Category:Merkel cell carcinoma regimens
Category:Disease-specific pages
Category:Non-melanoma skin cancers
Category:Null regimens
Mesna (Mesnex)

==General information==
Class/mechanism: Detoxifying agent to reduce the risk of hemorrhagic cystitis with agents such as Ifosfamide (Ifex). Mesna is rapidly metabolized to mesna disulfide (dimesna), which remains intravascular and is rapidly processed by the kidneys, where it is converted back into mesna. Mesna binds to the urotoxic metabolites of ifosfamide, acrolein and 4-hydroxy-ifosfamide, limiting the risk of hemorrhagic cystitis. It has not been shown to interfere with antitumor efficacy.Mesna (Mesnex) package insertMesna (Mesnex) package insert (locally hosted backup)
Route: IV, PO
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Patient drug information==
*Mesna (Mesnex) package insert PDF page 14-16
*Mesna (Mesnex) patient drug information (Chemocare)Mesna (Mesnex) patient drug information (Chemocare)
*Mesna (Mesnex) patient drug information (UpToDate)Mesna (Mesnex) patient drug information (UpToDate)
==History of changes in FDA indication==
*1988-12-30: Initial FDA approval 
==Also known as==
*Brand names: Anti Uron, Mesa, Mesnex, Mesnil, Mestian, Mistabron, Mistabronco, Mitexan, Mucolene, Neper, Novacarel, Siruta, Uromes, Uromitexan, Uroprot, Varimesna
==References==
Category:Drugs
Category:Intravenous medications
Category:Oral medications
Category:Chemotherapy protective agents
Category:FDA approved in 1988
Category:WHO Essential Cancer Medicine
Methoxsalen (Uvadex)

==General information==
Class/mechanism: Psoralen/furocoumarin. Photoactive substance used for palliative photopheresis/extracorporeal phototherapy of cutaneous T-cell lymphoma (CTCL). Exact mechanism of action unknown, but photoactivation of methoxsalen is believed to result in its conjugation and formation of covalent bonds with DNA and possibly proteins. Additions to single strands of DNA and crosslinking of methoxsalen to two strands of DNA occur.Methoxsalen (Uvadex) package insertMethoxsalen (Uvadex) package insert (locally hosted backup)Therakos manufacturer's website
Route: IV (other formulations of methoxsalen also available in PO & topical forms)
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information. 
==Diseases for which it is used==
*Cutaneous T-cell lymphoma
==Patient drug information==
*Patient information about Therakos photopheresisPatient information about Therakos photopheresis
*Methoxsalen (Uvadex) patient drug information (UpToDate)Methoxsalen (Uvadex) patient drug information (UpToDate)
==History of changes in FDA indication==
* 1999-02-25: Initial FDA approval for extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. (Based on Edelson et al. 1987)
* 2013-10-31: Indication revised for extracorporeal administration with the UVARTM XTSTM or THERAKOSTM CELLEXTM Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment. (No supporting studies are cited)
==History of changes in EMA indication==
*1958-03-31: EURD
==Also known as==
Photopheresis systems that methoxsalen is used with may be called UVAR XTS, Therakos, or Therakos Cellex. 
*Generic names: 8-MOP, methoxypsoralen
*Brand names: Ammoidin, Oxsoralen, Oxsoralen-Ultra, Uvadex, Xanthotoxin, Deltasoralen, Dermox, Geralen, Geroxalen, Meladinina, Meladinine, Metoxaleno, Mopsoralen, Puvasoralen, Ultramop
==References==
Category:Drugs
Category:Intravenous medications
Category:Furanocoumarins
Category:Cutaneous T-cell lymphoma medications
Category:FDA approved in 1999
Category:EMA approved in 1958